The CYP 17 and CYP 19 genes encode 17alpha-hydroxylase/17,20-lyase and aromatase, respectively, both involved in sex hormone synthesis. We investigated the association between 2 common polymorphisms in 1) the promoter region (T-->C substitution) of CYP 17, and 2) exon 3 (G-->A) of CYP 19, bone mineral density (BMD) and serum androgen/estradiol, in a case-control study of 252 postmenopausal women aged 64.5 +/- 9.2 yr ( mean +/- SD). There was no significant difference in serum estradiol concentrations between cases ( n = 136) and controls ( n = 116). The CYP 19 genotype was significantly associated with serum estradiol ( P = 0.002). Women with the AA genotype had higher serum estradiol concentrations compared with those with the GG genotype ( P = 0.03). In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis ( P = 0.04) and fractures ( P = 0.003). We found no significant association between CYP 17 genotype and serum androgens and estradiol concentrations. However, a significant association was seen between BMD values at the femoral neck with CYP 17 genotype in cases ( P = 0.04) and in the whole study population (P = 0.012). Subjects with the CC genotype had significantly lower BMD ( mean +/- SD: TT, 0.7 +/- 0.16; CC, 0.6 +/- 0.08 g/cm(2); P = 0.006). In conclusion, both CYP 17 and CYP 19 are candidate genes for osteoporosis in postmenopausal women.
- BREAST-CANCER RISK